Key result
Reduced antithrombin-mediated thrombin inactivation is linked to ~10% higher recurrent VTE risk.
Why the study?
Are thrombin generation and thrombin dynamic parameters associated with recurrent VTE after anticoagulation withdrawal in patients with prior VTE?
Cohort (n=589)
Are thrombin generation and thrombin dynamic parameters associated with recurrent VTE after anticoagulation withdrawal in patients with prior VTE?
Thrombin generation and dynamic parameters, specifically reduced thrombin inactivation and thrombomodulin sensitivity, may help identify patients at higher risk for recurrent VTE after stopping anticoagulation.
Answers are grounded in this paper and cite their sources.
Should not yet guide anticoagulation duration after unprovoked VTE; hypothesis-generating for thrombin generation biomarkers in recurrence risk.
BACKGROUND: Recurrent venous thromboembolism (VTE) is a major concern after stopping anticoagulation. Thrombin generation (TG) parameters-including thrombomodulin (TM) sensitivity-have been proposed as biomarkers of recurrence, but findings remain inconsistent. The role of thrombin dynamic (TD) parameters, including prothrombin conversion and thrombin inactivation, is unclear. OBJECTIVES: This study evaluated whether TG and TD parameters are associated with VTE recurrence. METHODS: In 589 patients from the prospective VISTA study, TG was measured during anticoagulation and 1 month after stopping vitamin K antagonist therapy. TM sensitivity was quantified as the percentage inhibition of endogenous thrombin potential (ETP) and peak thrombin concentration. TD parameters were derived computationally from TG curves. Cox regression was used to evaluate associations with recurrent VTE >2 years, including subgroup analyses excluding hormone-related events. RESULTS: During the 2-year follow-up, 63 patients experienced recurrent VTE. In multivariable Cox regression adjusted for age, sex, index event type, and hormone use, reduced thrombin inactivation by antithrombin was associated with recurrence (per 100-unit decrease-hazards ratio [HR], 1.10; 95% CI, 1.00-1.20). In patients without hormone-related VTE, lower ETP and reduced TM-mediated inhibition of peak thrombin concentration were also significantly associated with recurrence (ETP per 100-unit decrease-HR, 1.11; 95% CI, 1.01-1.21; TM sensitivity per 10% decrease-HR, 1.26; 95% CI, 1.00-1.58). Other TG parameters were not significantly associated with recurrence. CONCLUSION: Reduced ETP, TM sensitivity, and thrombin inactivation were associated with VTE recurrence in people with unprovoked VTE. These biomarkers may have potential to identify patients at higher risk of recurrence.
No takes yet. Share an insight, caveat, or question.
Poolen et al. (2026) conducted a cohort in Recurrent venous thromboembolism (n=589). Reduced thrombin inactivation by antithrombin was evaluated on Recurrent VTE (HR 1.10, 95% CI 1.00-1.20). Reduced thrombin inactivation by antithrombin was associated with recurrent VTE (HR 1.10; 95% CI 1.00-1.20 per 100-unit decrease) after stopping anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: